SFM
GNCA

Sphera Funds Management’s Genocea Biosciences, Inc. GNCA Stock Holding History

Sphera Funds Management’s Portfolio GNCA Stock Details GNCA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-61,250
Closed -$715K – 163
2017
Q3 		$715K Hold
61,250
– – 0.1% 107
2017
Q2 		$2.56M Sell
61,250
-19,534
-24% -$940K 0.43% 71
2017
Q1 		$3.94M Sell
80,784
-6,250
-7% -$244K 0.77% 33
2016
Q4 		$2.87M Buy
87,034
+10,875
+14% +$358K 0.73% 39
2016
Q3 		$3.12M Sell
76,159
-12,500
-14% -$490K 0.51% 50
2016
Q2 		$2.91M Buy
88,659
+43,420
+96% +$1.59M 0.76% 40
2016
Q1 		$2.8M Sell
45,239
-22,322
-33% -$709K 0.61% 31
2015
Q4 		$2.85M Buy
67,561
+20,411
+43% +$973K 0.42% 60
2015
Q3 		$2.58M Buy
47,150
+9,375
+25% +$930K 0.33% 75
2015
Q2 		$4.15M Buy
37,775
+22,250
+143% +$2.07M 0.41% 55
2015
Q1 		$1.47M Buy
+15,525
New +$1.1M 0.15% 123

Other funds holding GNCA

PVMCV
Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NC
Northpointe Capital Bloomfield Hills, Michigan $258M AUM 1.97% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
AA
AlphaMark Advisors Ft. Wright, Kentucky $231M AUM 19.98% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Sphera Funds Management's GNCA Position: Q4 2017 in Review

Sphera Funds Management sold out of Genocea Biosciences, Inc. (GNCA) in Q4 2017, closing a stake of 61,250 shares — an estimated $715K sold.

Sphera Funds Management first reported a position in GNCA in Q1 2015 and held it in 11 quarters. The position peaked at $4.15M in Q2 2015. 56 funds tracked by Wall St. Rank hold GNCA as of Q4 2017.

  • Sphera Funds Management reported no remaining Genocea Biosciences, Inc. position as of Q4 2017 after selling out during the quarter.
  • Sphera Funds Management sold 61,250 Genocea Biosciences, Inc. shares in Q4 2017, an estimated $715K.
  • Sphera Funds Management first reported a position in Genocea Biosciences, Inc. in Q1 2015 and held it in 11 quarters.
  • Sphera Funds Management's Genocea Biosciences, Inc. position peaked at $4.15M in Q2 2015.
  • 56 funds tracked by Wall St. Rank held Genocea Biosciences, Inc. as of Q4 2017.

Based on Sphera Funds Management's 13F filing for Q4 2017, filed 12 Feb 2018.